ANDA 211625, held by Nivagen. Succinylcholine Chloride.
As of Nov 16, 2026, ANDA 211625 (Succinylcholine Chloride), held by Nivagen, was first approved by FDA on May 19, 2020, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 19, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Succinylcholine Chloride20MG/ML · injectable;injection | Succinylcholine Chloride | Rx |
| Apr 7, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Oct 26, 2021 | Supplement 1Labeling · Standard review | Approved | None posted |
| May 19, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters